Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11287-11295

  Chen, Yanping ^a   Song, Jinlian ^a   Jiang, Yuhong ^a   Yu, Chundong ^a   Ma, Zhongliang ^b  

^a Qingdao Women and Children Health Care Centers   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Breast cancer; CD24; CD44; Chemotherapy; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHILD; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CHILD; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85012977518     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
3. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004; 35: 255-262.
4. Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 2015; 55: 4717-21.
5. Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 1990; 137: 895-905.
6. Raife TJ, Lager DJ, Kemp JD, Dick FR. Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. Am J Clin Pathol 1994; 101: 296-299.
7. Jiao XI, Zhao C, Niu M, Chen D. Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells. Eur Rev Med Pharmacol Sci 2013; 17: 1709-1715.
8. Ma ZL, Chen YP, Song JL, Wang YQ. Knockdown of CD24 inhibits proliferation, invasion and sensitizes breast cancer MCF-7 cells to tamoxifen in vitro. Eur Rev Med Pharmacol Sci 2015; 19: 2394-2399.
9. Zhang YH, Wang ZY, Hao FY, Zhang L. Cluster of differentiation 24 monoclonal antibody induces apoptosis in the osteosarcoma cells. Eur Rev Med Pharmacol Sci 2014; 18: 2038-2041.
10. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, Lee JH, Kim HR. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 2012; 41: 211-8.
11. Andratschke M, Chaubal S, Pauli C, Mack B, Hagedorn H, Wollenberg B. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer. Anticancer Res 2005; 25: 2821-6.
12. Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 2012; 12: 458.
13. Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 2011; 178: 956-63.
14. Xie Z, Choong PF, Poon LF, Zhou J, Khng J, Jasinghe VJ, Palaniyandi S, Chen CS. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 2008; 62: 949-57.
15. Herrera-Gayol A, Jothy S. CD44 modulates Hs578T human breast cancer cell adhesion, migration, and invasiveness. Exp Mol Pathol 1999; 66: 99-108.
16. Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C, Esteva FJ. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat 2015; 151: 501-13.
17. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
18. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
19. Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ. CD44+/ CD24-markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol 2015; 37: 58-63.
20. + phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 2012; 133: 979-95.
21. Kristiansen G, Sammar M, Altevogt P. Tumor biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004; 35: 255-62.
22. McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N, Hill A, McCarthy HO, Young LS, Kay EW, Isacke CM, Waugh DJ. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget 2015; 6: 11465-76.
23. Klingbeil P, Natrajan R, Everitt G, Vatcheva R, Marchio C, Palacios J, Buerger H, Reis-Filho JS, Isacke CM. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 2010; 120: 95-109.
24. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-5511.
25. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A 2010; 107: 3722-3727.
26. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11: 1154-9.
27. + tumor cells in invasive breast carcinomas. Hum 2008; 39: 1096-102.
28. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24-phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 2011; 28: 745-52.
29. - phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res 2012; 31: 59.
30. Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO. A CD44-/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 2012; 133: 979-95.